Leukotriene and prostaglandin production after infusion of tumour necrosis factor in man. 1991

K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
Liver Unit, King's College School of Medicine and Dentistry, London, UK.

Tumor necrosis factor-alpha is believed to be an important mediator of endotoxaemia and septic shock, the effects of which are thought to be mediated through the generation of cysteinyl-leukotrienes, thromboxane A2 and other prostanoids. We have investigated the production of these eicosanoids and also that of prostacyclin in vivo after infusion of tumor necrosis factor-alpha into 4 subjects with a chronic hepatitis B virus infection. This resulted in plasma TNF levels considerably greater than those observed in septic shock. Urinary excretion rate of leukotriene E4 increased by 2 to 3-fold in all subjects by 8 h following TNF infusion. Urinary excretion of thromboxane B2 and 6-oxo-prostaglandin F1 alpha, however, increased in the first 4 h in 3/4 subjects by 2 to 40-fold and returned towards baseline by 8 h. Excretion of the hepatic metabolite, 2,3-dinor 6-oxo-prostaglandin F1 alpha, increased in all subjects (2 to 4-fold at 4h). We conclude that there is increased production of cysteinyl leukotrienes, thromboxane A2 and prostacyclin after infusion of tumour necrosis factor into man.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013189 SRS-A A group of LEUKOTRIENES; (LTC4; LTD4; and LTE4) that is the major mediator of BRONCHOCONSTRICTION; HYPERSENSITIVITY; and other allergic reactions. Earlier studies described a "slow-reacting substance of ANAPHYLAXIS" released from lung by cobra venom or after anaphylactic shock. The relationship between SRS-A leukotrienes was established by UV which showed the presence of the conjugated triene. (From Merck Index, 11th ed) Slow Reacting Substance of Anaphylaxis
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
December 1997, Prostaglandins, leukotrienes, and essential fatty acids,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
February 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
July 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
March 1993, Archives of disease in childhood,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
June 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
December 1988, European journal of immunology,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
December 1987, British journal of cancer,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
January 1987, Ciba Foundation symposium,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
October 1993, International journal of experimental pathology,
K P Moore, and N Sheron, and P Ward, and G W Taylor, and G J Alexander, and R Williams
October 1992, International journal of experimental pathology,
Copied contents to your clipboard!